Advertisement
INCY or IONS or PFE
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Ionis Pharmaceuticals (IONS) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- INCY shares have shown resilience amid oncology portfolio growth, with European approval for Zynyz boosting sentiment despite a recent modest pullback.
- IONS delivered strong Q4 revenue growth of 34% year-over-year, supported by commercial launches like TRYNGOLZA and priority FDA review for olezarsen.
- PFE advanced with positive mid-stage data for eczema drug tilrekimig and weight management approval in China, aiding diversification efforts.
- IONS exhibits superior one-year returns around 126%, contrasting INCY's 49% surge and PFE's more stable 6-10% gains.
- All three operate in biotech/pharma, but PFE offers scale and dividends, while INCY and IONS focus on specialized pipelines with higher volatility.
- Recent momentum favors IONS on revenue beats and catalysts, positioning it strongly in relative performance.
Introduction
This stock comparison evaluates INCY, IONS, and PFE amid evolving biotech and pharmaceutical landscapes. These companies span oncology, RNA-targeted therapies, and broad biopharma portfolios, offering insights into growth drivers, regulatory progress, and market positioning. Traders seeking momentum in specialized biotech may eye INCY and IONS, while investors favoring stability and diversification might prefer PFE. Recent earnings, approvals, and pipeline updates highlight contrasts in relative performance and sector exposure, aiding decisions in volatile markets.
INCY Overview and Recent Performance
Incyte Corporation (INCY) is a biopharmaceutical firm focused on oncology and inflammation therapeutics, with key products like Jakafi driving revenue. In recent market activity, INCY shares experienced a roughly 6.5% decline over the past month but maintain strength from robust Q4 earnings and a 14% five-year compounded annual revenue growth. European Commission approval for oncology drug Zynyz has expanded its portfolio, enhancing sentiment despite short-term pressures. The stock has surged 49% over the past year, outperforming broader indices in recent weeks on pipeline potential and financial solidity.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) specializes in RNA-targeted medicines for rare diseases, with marketed products including TRYNGOLZA, WAINUA, and SPINRAZA. Recent performance reflects Q4 2025 revenue of $203 million, up from prior periods and beating estimates by 30%, contributing to full-year growth of 34%. Priority FDA review for olezarsen in hypertriglyceridemia, with a June PDUFA date, alongside strong TRYNGOLZA sales of $108 million, has fueled optimism. One-year returns exceed 126%, with YTD gains around 5%, though shares dipped modestly in recent weeks amid broader biotech volatility.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a global biopharma leader with a diverse portfolio spanning vaccines, oncology, and internal medicine. In recent weeks, positive mid-stage results for eczema candidate tilrekimig and approval of a weight management drug in China have supported shares, up about 9-10% YTD and 6-7% over one year. These developments aid post-COVID diversification, countering patent cliffs. Trading around $27, PFE reflects stability with modest monthly gains amid sector rotations, bolstered by ongoing pipeline advancements.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. These bots employ AI/ML for trend trading, dip buying, hedging, and volatility plays, with timeframes from 5 minutes to 62 days. Featured bots display impressive stats: annualized returns up to +217%, win rates of 53-95%, profit factors ranging 1.57-8.99, and profit-to-drawdown ratios to 22.68. Examples include a 25-ticker agent at +132% annualized (62% win rate) in semis/oil/aerospace, and small-cap trend traders at +99% (56% win rate). Ideal for current conditions, they adapt to momentum and rotations. Explore Trending AI Robots to identify suitable options for your portfolio.
Head-to-Head Comparison
INCY, IONS, and PFE contrast in scale and focus: PFE's broad business model spans global markets with stable revenues, unlike biotech peers' niche oncology (INCY) and RNA therapies (IONS). Growth drivers differ—IONS leverages 34% revenue acceleration and Phase 3 catalysts, INCY oncology approvals, while PFE diversifies via new indications. Recent momentum favors IONS (126% one-year) over INCY (49%) and PFE (7%). Risks include pipeline setbacks for biotechs versus PFE's patent exposures. Valuation sensitivity is higher for growth-oriented INCY/IONS, with PFE at a peer-premium P/E. Sentiment tilts toward IONS on earnings beats, balancing PFE's scale.
Tickeron AI Verdict
Tickeron’s AI currently favors IONS based on trend consistency from revenue growth, commercial momentum, and near-term catalysts like olezarsen review, outperforming peers in relative positioning. INCY shows pipeline stability, but PFE lags in momentum despite lower risk. Probabilistic edge to IONS for traders eyeing biotech upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s), and PFE’s TA Score reflects 4 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 4 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.43% price change this week, while IONS (@Biotechnology) price change was -0.11% , and PFE (@Pharmaceuticals: Major) price fluctuated +0.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.13%. For the same industry, the average monthly price growth was +4.07%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
INCY is expected to report earnings on Apr 28, 2026.
IONS is expected to report earnings on Apr 29, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.13% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INCY | IONS | PFE | |
| Capitalization | 19.3B | 12.4B | 157B |
| EBITDA | 1.76B | -273.12M | 16.8B |
| Gain YTD | -1.873 | -5.360 | 12.373 |
| P/E Ratio | 15.12 | N/A | 20.24 |
| Revenue | 5.14B | 944M | 62.6B |
| Total Cash | 3.58B | 2.68B | 13.6B |
| Total Debt | 40.4M | 2.07B | 64B |
INCY | IONS | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 8 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 100 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 71 | 45 | 100 | |
SMR RATING 1..100 | 32 | 98 | 74 | |
PRICE GROWTH RATING 1..100 | 47 | 41 | 27 | |
P/E GROWTH RATING 1..100 | 100 | 76 | 37 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (69) in the Biotechnology industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than INCY’s and significantly faster than IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (45) in the Biotechnology industry is in the same range as INCY (71) in the Biotechnology industry, and is somewhat better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that IONS's stock grew similarly to INCY’s and somewhat faster than PFE’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for PFE (74) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that INCY's stock grew somewhat faster than PFE’s and significantly faster than IONS’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as IONS (41) in the Biotechnology industry, and is in the same range as INCY (47) in the Biotechnology industry. This means that PFE's stock grew similarly to IONS’s and similarly to INCY’s over the last 12 months.
PFE's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (76) in the Biotechnology industry, and is somewhat better than the same rating for INCY (100) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than IONS’s and somewhat faster than INCY’s over the last 12 months.
| INCY | IONS | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 69% | 1 day ago 73% | N/A |
| Stochastic ODDS (%) | 1 day ago 56% | 1 day ago 66% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 71% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 77% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 66% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 74% | 1 day ago 51% |
| Advances ODDS (%) | 13 days ago 61% | 7 days ago 66% | 5 days ago 56% |
| Declines ODDS (%) | 6 days ago 60% | 9 days ago 65% | 12 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 64% | 1 day ago 67% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 75% | 1 day ago 53% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EWZS | 16.21 | 0.13 | +0.81% |
| iShares MSCI Brazil Small-Cap ETF | |||
| BSVO | 27.34 | 0.12 | +0.44% |
| EA Bridgeway Omni Small-Cap Value ETF | |||
| SARK | 28.16 | 0.11 | +0.39% |
| Tradr 1X Short Innovation Daily ETF | |||
| JEMB | 53.92 | 0.15 | +0.27% |
| Janus Henderson Em Mkts Dbt Hrd Ccy ETF | |||
| ABFL | 76.91 | -0.01 | -0.01% |
| Abacus FCF Leaders ETF | |||